Targeted Oncology· @TargetedOnc · X·· 23 hours agoScore70
Body
KEYNOTE-B49 at #ESMO26 raises a fundamental question:
PFS improved (HR 0.74), but median PFS was 6.7 vs 6.0 months, with no OS benefit (HR 1.04).
Are we looking at a statistically positive trial or a clinically meaningful advance?
#BreastCancer
63 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA51matched by Proffered paper 2: Breast cancer, early and advanced stage
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.orgSource: Targeted Oncology · x.com